|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Journal of the American Society of Nephrology|
|State||Published - Sep 2021|
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
Access to Document
Other files and links
Evolving demographics of nephrology research workforce in the united states. / Quaggin, Susan E.; Humphreys, Benjamin D.In: Clinical Journal of the American Society of Nephrology, Vol. 16, No. 9, 09.2021, p. 1312-1314.
Research output: Contribution to journal › Editorial › peer-review
TY - JOUR
T1 - Evolving demographics of nephrology research workforce in the united states
AU - Quaggin, Susan E.
AU - Humphreys, Benjamin D.
N1 - Funding Information: Additional steps needed to increase kidney research include shortening the time period from graduation to obtaining career development awards and independent funding, which will require more dollar investment from federal agencies; providing mechanisms and resources to protect the time of junior investigators; and expanding the already highly successful student loan repayment programs. Organizations like the American Society of Nephrology (ASN) and American Society for Clinical Investigation are committed to building future generations of physician-scientists and investigators. For example, ASN has launched a student loan mitigation program; funds career development awards through Kidney Cure; and partners with organizations, including the Harold Amos Medical Faculty Development Program, to fund research grants. Likewise, the American Society for Clinical Investigation promotes the interests of physician trainees through its annual meetings, Young Physician-Scientists Award, partnership with the American Physician Scientists Association, and advocacy to critical stakeholders. Funding Information: And, indeed, these data should not surprise us: it is common for physician-scientists to spend 15 years in training before they become competitive to obtain NIH Career Development (K) awards, often the first step toward a tenure track faculty position. Health care systems in the United States increasingly measure physician productivity by relative value unit–based systems, leaving little room in the annual budget to provide protected time, even for the most promising of young researchers. As the length of time from submission to successful notice of award increases, these fiscal challenges only grow larger. Furthermore, institutions at NIH must compete for funding dollars, which ultimately affects the pipeline of researchers. In the congressional COVID-19 emergency funding packages, which provided $945 million to the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) did not receive any funding for COVID-19–related kidney research. This is in contrast to the $100 million awarded to the National Heart, Lung, and Blood Institute. Nephrology is a subspecialty serving on the frontlines of the pandemic, so this discrepancy is baffling. AKI was reported in 30%–70% of all patients hospitalized with COVID-19 (6,7), and an estimated 47% of patients who developed AKI in one Veterans Affairs cohort left hospital without full recovery of kidney function (8). Furthermore, during the first 7 months of the COVID-19 pandemic, it is estimated that approximately 7000–10,000 excess deaths occurred in patients on dialysis (9). COVID-19–related mortality was reported as four-fold higher in patients on dialysis. Although the full effect of COVID-19 on new cases of CKD in the country is not Funding Information: B.D. Humphreys reports having patents and inventions with AG and Evotec; serving on the editorial boards of the American Journal of Physiology Renal Physiology, JCI Insight, Kidney International, RegMed XB, and Seminars in Nephrology; serving as vice president of the American Society for Clinical Investigation; receiving honoraria from the American Society of Nephrology; having ownership interest in Chinook Therapeutics; receiving research funding from Chinook Therapeutics and Janssen; having consultancy agreements with Chinook Therapeutics, Janssen, and Pfizer; serving on the scientific advisory boards of Chinook Therapeutics and Regenerative Medicine Crossing Borders; serving as an associate editor of JASN; and serving on the board of scientific advisors of NIDDK. S.E. Quaggin reports serving as the president of the American Society of Nephrology and as chief scientific officer and founder of Mannin Research; having consultancy agreements with AstraZeneca, Genentech, Goldfinch, Janssen, Lowy Medical Research Foundation, Novartis, and Roche; serving as a scientific advisor or member of AstraZeneca, Genentech/Roche, JCI, Karo-linska Cardiovascular, Renal and Metabolism Institute, Lowy Medical Research Institute, Mannin, and Novartis; receiving research funding from AstraZeneca and Mannin Research; and receiving honoraria from the Korea Advanced Institute of Science and Technology (for plenary lecture).
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85115606717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115606717&partnerID=8YFLogxK
U2 - 10.2215/CJN.09950721
DO - 10.2215/CJN.09950721
M3 - Editorial
C2 - 34497108
AN - SCOPUS:85115606717
VL - 16
SP - 1312
EP - 1314
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
SN - 1555-9041
IS - 9